Chengbin Wu – CEO, EpimAb Biotherapeutics, China
Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific…
GBI
Last updated: 13.02.2014
Address: Suite 301, Building 2
169 Mengzi Road
Shanghai, 200032 P.R. China
Tel: +86(21) 53022951
Web: http://www.gbipharma.com/
Company description
Gbipharma.com is an information, business intelligence, and consulting company which has been servicing the pharmaceutical, biotechnology, and healthcare sectors, as well as investors and other financial and consulting service providers since 2002. We aim to provide a total information solution for companies within or intending to enter China’s market.
Gbipharma.com’s content and tools are targeted at individuals within marketing, business development, R&D, and operations functions up through top country and regional management levels. Our information products include the “China Pharmaceutical & Biotechnology Monthly”, the definitive English-language publication covering China’s pharma and healthcare sectors, and SOURCE, the ultimate (bilingual) information database service for pharmaceuticals in China.
GBI’s content has been created through rigorous primary and secondary research. Information is not easy to collect in China, and much misinformation exists. (Even publicly available data may be hard to compile, poorly organized, and non-standard, often rendering the information essentially unusable in its raw forms.) GBI’s analysts and managers have extensive experience in China’s pharmaceutical and healthcare sectors and are committed to creating meaningful, timely, and actionable information for their clients.
Products and services
Information Services, Consulting
Interviews
Related
China / Antitrust Threat to Pharma; June BioNTech Vaccine Approval; EpimAb IPO; CanSino Inhaled Vaccine Trials
The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in…
China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
China / Public Insurance Coverage for Rare Disease Patients: Beijing & Shanghai Surprisingly Low in New City Ranking
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
China / AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan for Pharmaron; Clover’s $230 Million Investment Boost
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
China / Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
China / HiFiBiO CEO on the Keys to Global Biotech Success
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
China / New Drug Approvals 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Liang Schweizer – CEO & CSO, HiFiBiO Therapeutics
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
China / National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
China / New Year, New Round of Drug Price Cuts
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
China / 5 Top Trends in Healthcare & Biopharma in 2020
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
